Back to top
more

Enzo Biochem (ENZ)

(Delayed Data from NYSE)

$1.16 USD

1.16
87,843

+0.05 (4.50%)

Updated Jul 12, 2024 04:00 PM ET

After-Market: $1.16 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Roche (RHHBY) Announces Positive Data on Hemophilia A Drug

by Zacks Equity Research

Roche Holdings AG (RHHBY) announced positive data from the phase III study, HAVEN 1, on hemophilia A candidate emicizumab.

    Alnylam (ALNY) Stock Down Despite Positive Hemophilia Data

    by Zacks Equity Research

    Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi's (SNY) specialty care global business unit, Genzyme, announced encouraging results from the ongoing phase II open-label extension (OLE) study.

      Alnylam Commences Phase III Study for Hemophilia Candidate

      by Zacks Equity Research

      Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi's (SNY) announced that it has commenced phase III ATLAS study for its candidate fitusiran.

        Prima Biomed's Intra-Tumor Study on Lead Candidate Approved

        by Zacks Equity Research

        Prima Biomed Ltd. (PBMD) announced that a new clinical study, INSIGHT, on its lead candidate IMP321 has received regulatory approval for initiation

          DBV Technologies (DBVT) Worth a Look: Stock Up 5.7%

          by Zacks Equity Research

          DBV Technologies S.A. (DBVT) was a big mover last session, as the company saw its shares rise nearly 6% on the day.

            Endo (ENDP) to Remove Opioid Pain Drug Opana ER from Market

            by Zacks Equity Research

            Endo International plc (ENDP) recently announced that it will withdraw opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market following FDA's request in June.

              Shire Completes NDA Filing for Hemophilia Drug with FDA

              by Zacks Equity Research

              Shire plc (SHPG) recently announced that it has filed an investigational new drug (IND) application with the FDA, seeking approval for its recombinant factor VIII (FVIII) gene therapy candidate, SHP654, for the treatment of patients with Hemophilia A.

                Alexion Reportedly Being Investigated by HHS, Shares Slip

                by Zacks Equity Research

                Shares of Alexion Pharmaceuticals, Inc. (ALXN) were down more than 3% on Thursday after a Bloomberg report stated that it is under investigation by the U.S. Department of Health and Human Services' (HHS) Office of Inspector General (OIG).

                  ProQR's Usher Syndrome Candidate Gets Orphan Drug Status

                  by Zacks Equity Research

                  ProQR Therapeutics N.V. (PRQR) announced that its key pipeline candidate, QRX-411, has been granted orphan drug designation by the FDA and European Medicines Agency (EMA) for the treatment of retinitis pigmentosa.

                    Blueprint Medicines (BPMC) Shows Strength: Stock Adds 9.6% in Session

                    by Zacks Equity Research

                    Blueprint Medicines Corporation (BPMC) was a big mover last session, as the company saw its shares rise nearly 10% on the day.

                      Abeona Therapeutics (ABEO) Catches Eye: Stock Jumps 10.6%

                      by Zacks Equity Research

                      Abeona Therapeutics Inc. (ABEO) moved big last session, as the company saw its shares rise over 10% on the day.

                        Sucampo (SCMP) Remains Focused on Amitza Label Expansion

                        by Zacks Equity Research

                        We issued an updated report on Sucampo Pharmaceuticals, Inc. (SCMP) on July 4.

                          AMAG Pharmaceuticals Focuses on Product Development & Buyouts

                          by Zacks Equity Research

                          We issued an updated report on AMAG Pharmaceuticals, Inc. (AMAG) on Jul 4.

                            BeiGene (BGNE) Surges: Stock Moves 20.8% Higher

                            by Zacks Equity Research

                            BeiGene (BGNE) was a big mover last session, as the company saw its shares rise almost 21% on Monday amid huge volumes.

                              Bayer Starts Phase III Study for Uterine Fibroids' Candidate

                              by Zacks Equity Research

                              Bayer Aktiengesellschaft (BAYRY) announced that it has enrolled the first patient in a phase III study ASTEROID which will evaluate vilaprisan in women suffering from uterine fibroids.

                                Marinus' (MRNS) Ganaxolone Gets Orphan Drug Status in US

                                by Zacks Equity Research

                                Marinus Pharmaceuticals, Inc. (MRNS) announced that the FDA has granted orphan drug designation to its key candidate, ganaxolone, for the treatment of adult and pediatric patients with CDKL5 disorder.

                                  Esperion's Combo Cholesterol Candidate Enters Phase III

                                  by Zacks Equity Research

                                  Esperion Therapeutics, Inc. (ESPR) received positive feedback from the FDA for initiation of a phase III bridging study, evaluating the combination of bempedoic acid (180 mg) and Zetia (10 mg) for an LDL-C lowering indication.

                                    Jeffrey Hymen headshot

                                    5 Biomedical Stocks That Are Expected To Surge

                                    by Jeffrey Hymen

                                    With the promise of regulatory reform on the horizon, investors have been excited about the biomedical space throughout the year. If you want to add some to your portfolio, check out these 5 biomedical stocks that are primed to skyrocket here.

                                      Surging Earnings Estimates Signal Good News for Enzo Biochem (ENZ)

                                      by Zacks Equity Research

                                      Enzo Biochem (ENZ) is seeing positive earnings estimate revisions suggesting that it could be a solid choice for investors.

                                        Enzo Biochem (ENZ) Shares March Higher, Can It Continue?

                                        by Zacks Equity Research

                                        Enzo Biochem, Inc. (ENZ) has been on the move lately as the stock has risen by 19.1% in the past four weeks, and it is currently trading well above its 20-Day SMA

                                          Looking for a Top Momentum Stock? 3 Reasons Why Enzo Biochem (ENZ) is a Great Choice

                                          by Zacks Equity Research

                                          Enzo Biochem (ENZ) is a solid momentum stock that has a favorable Zacks Rank and is seeing solid earnings estimate revisions.

                                            Enzo Biochem (ENZ) Looks Good: Stock Jumps 13.3% in Session

                                            by Zacks Equity Research

                                            Enzo Biochem, Inc. (ENZ) shares rose above 13% in the last trading session.

                                              Merrimack (MACK) Q1 Loss Wider than Expected, Sells Onivyde

                                              by Zacks Equity Research

                                              Merrimack Pharmaceuticals, Inc. (MACK) reported a loss of 22 cents per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 7 cents. The company had reported a loss of 32 cents in the year-ago quarter.

                                                Orexigen Posts Wider-than-Expected Loss in Q1, Sales Up Y/Y

                                                by Zacks Equity Research

                                                Orexigen Therapeutics, Inc.'s (OREX) loss of $4.67 per share in the first quarter of 2017 was significantly wider than the Zacks Consensus Estimate of a loss of $2.60 and the year-ago loss of $1.54.

                                                  Alnylam (ALNY) Q1 Loss Wider than Expected, Revenues Up Y/Y

                                                  by Zacks Equity Research

                                                  Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.25 per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of $1.22 and the year-ago loss of $1.21.